Licensing

The idea of forming Transformative Biotech came years after its Founder & CEO, Russ Hullet, completed a thorough due diligence of Summit Biolab’s IP. Having invested in venture capital for more than 25 years, Russ recognized Summit’s disruptive new technologies as a rare and exceptional opportunity, and became Summit's lead investor for the capital that launched their operations and laboratory at the Fitzsimons/CU Anschutz Medical Campus. Here, Summit generated ~$14,000,000 in revenue in its first 16 months of operations, earning gross margins of more than 70% – a remarkable feat for a startup company! In 2023, Russ formed Transformative Biotech and entered into negotiations with Summit, which eventually led to the acquisition of Summit's intellectual property, including their patent-pending portfolio of technologies.

 

Transformative Biotech is seeking commercialization partners who share in our belief in the transformative potential of direct-to-PCR testing, and who are looking to deploy these disruptive new technologies in the market. Our partners will find themselves at the forefront of a new and exciting era in PCR, with several significant advantages over their competitors. 

 

Having closed on the acquisition of this proprietary IP in May of 2023, exclusive licensing rights are currently still available. Companies with a presence internationally, as well as the United States, would be ideal candidates for collaboration. 

 

For more detailed information and answers to any questions you may have, please contact us.